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Abstract
Fungal pathogens exploit diverse mechanisms to survive exposure to antifungal drugs. This poses concern given the limited
number of clinically useful antifungals and the growing population of immunocompromised individuals vulnerable to life-
threatening fungal infection. To identify molecules that abrogate resistance to the most widely deployed class of
antifungals, the azoles, we conducted a screen of 1,280 pharmacologically active compounds. Three out of seven hits that
abolished azole resistance of a resistant mutant of the model yeast Saccharomyces cerevisiae and a clinical isolate of the
leading human fungal pathogen Candida albicans were inhibitors of protein kinase C (PKC), which regulates cell wall
integrity during growth, morphogenesis, and response to cell wall stress. Pharmacological or genetic impairment of Pkc1
conferred hypersensitivity to multiple drugs that target synthesis of the key cell membrane sterol ergosterol, including
azoles, allylamines, and morpholines. Pkc1 enabled survival of cell membrane stress at least in part via the mitogen
activated protein kinase (MAPK) cascade in both species, though through distinct downstream effectors. Strikingly,
inhibition of Pkc1 phenocopied inhibition of the molecular chaperone Hsp90 or its client protein calcineurin. PKC signaling
was required for calcineurin activation in response to drug exposure in S. cerevisiae. In contrast, Pkc1 and calcineurin
independently regulate drug resistance via a common target in C. albicans. We identified an additional level of regulatory
control in the C. albicans circuitry linking PKC signaling, Hsp90, and calcineurin as genetic reduction of Hsp90 led to
depletion of the terminal MAPK, Mkc1. Deletion of C. albicans PKC1 rendered fungistatic ergosterol biosynthesis inhibitors
fungicidal and attenuated virulence in a murine model of systemic candidiasis. This work establishes a new role for PKC
signaling in drug resistance, novel circuitry through which Hsp90 regulates drug resistance, and that targeting stress
response signaling provides a promising strategy for treating life-threatening fungal infections.
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Introduction
Microbial survival depends critically upon coordination of
sensing environmental stimuli with control of the appropriate
cellular responses. As a consequence, microbes have evolved
elaborate mechanisms to sense and respond to diverse environ-
mental stresses, including oxidative stress, osmotic stress, thermal
stress, changes in pH, and nutrient limitation [1,2]. Signal
transduction cascades integrate recognition and response to these
stresses as well as to challenges imposed by exposure to various
small molecules that are a ubiquitous presence in the environment.
Small molecules can have a dramatic effect on cellular signaling,
mediate communication between microbes, or exert potentially
lethal toxicity [3,4,5,6,7]. Many natural products are produced by
microbes in competitive communities and can lead to selection for
enhanced capacity to tolerate these agents. Since natural products
and their derivatives are extensively used in medicine and
agriculture [8,9], the evolution of resistance to these agents can
have profound consequences for human health.
The evolution of drug resistance in fungal pathogens poses
considerable concern given that invasive fungal infections are a
leading cause of human mortality worldwide, especially among
immunocompromised individuals. The frequency of such infec-
tions is on the rise in concert with the growing population of
patients with compromised immune systems due to chemotherapy,
transplantation of organs or hematopoietic stem cells, or infection
with HIV [10,11]. The leading fungal pathogen of humans is
Candida albicans, which ranks as the fourth most common cause of
hospital acquired infectious disease and is associated with mortality
rates approaching 50% [12,13,14]. There is a very limited
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treatment of fungal infections, in part due to the close evolutionary
relationships between these eukaryotic pathogens and their hosts
[15,16]. Most of the antifungal drugs in clinical use target the
biosynthesis or function of ergosterol, the main sterol of fungal
membranes [2,17,18]. The therapeutic efficacy of most antifungal
drugs is compromised by the emergence of drug resistant strains,
superinfection with resistant strains, and by static rather than cidal
activities that block fungal growth but do not eradicate the
pathogen population. To improve clinical outcome it will be
necessary to develop new antifungal drugs with different
mechanisms of action and to discover drugs that improve the
fungicidal activity of current antifungals.
The molecular basis of antifungal drug resistance is best
characterized in the context of the azoles through studies with C.
albicans and the model yeast Saccharomyces cerevisiae. The azoles have
been the most widely deployed class of antifungal drugs for decades
and inhibit lanosterol 14a-demethylase, encoded by ERG11,
resulting in a block in ergosterol biosynthesis, the accumulation of
a toxic sterol intermediate, and cell membrane stress [2,17,18]. The
azoles are generally fungistatic against Candida species and many
patients are on long-term therapy, creating favorable conditions for
the emergence of resistance. Despite the evolutionary distance
between C. albicans and S. cerevisiae, mechanisms of azole resistance
are largely conserved [19]. Resistance can arise by mechanisms that
minimize the impact of the drug on the fungus, such as the
overexpression of multidrug transporters or alterations of the drug
target that prevent the drug from inhibiting its target. Alternatively,
resistance can arise by mechanisms that minimize drug toxicity,
such as loss of function of the ergosterol biosynthetic enzyme Erg3,
which blocks the production of the toxic sterol that would otherwise
accumulate when the azoles inhibit Erg11. Recent studies have
established that basal tolerance of wild-type strains and resistance
duetomechanismsthat mitigatedrugtoxicitieswithoutblockingthe
effect of the drug on the cell are often dependent upon stress
responses that are critical for survival of azole-induced cell
membrane stress [2,18].
The key regulator of cellular stress responses implicated in both
basal tolerance and resistance to azoles is Hsp90 [2,18,20]. Hsp90
is an essential molecular chaperone that regulates the stability and
function of a diverse set of client proteins, many of which are
regulators of cellular signaling [21,22,23]. In S. cerevisiae and C.
albicans, inhibition of Hsp90 function blocks the rapid evolution of
azole resistance and abrogates resistance that was acquired by
diverse mutations [24,25]. A central aspect of Hsp90’s role in the
emergence and maintenance of azole resistance is that it enables
calcineurin-dependent stress responses that are required to survive
the membrane stress exerted by azoles. In both yeast species,
Hsp90 physically interacts with calcineurin keeping it in a stable
conformation that is poised for activation [26,27]. Inhibition of
calcineurin function phenocopies inhibition of Hsp90 function,
abrogating azole resistance of diverse mutants [24,25]. This has
led to the model that calcineurin is the key mediator of Hsp90-
dependent azole resistance. Notably, in C. albicans both Hsp90 and
calcineurin have recently been demonstrated to regulate resistance
to the echinocandins, the only new class of antifungals to reach the
clinic in decades; they inhibit the synthesis of (1,3)-b-D-glucan, a
key component of the fungal cell wall [20,27].
Another key cellular stress response pathway implicated in basal
tolerance to antifungal drugs is the protein kinase C (PKC) cell
wall integrity pathway, though it has only been implicated in
tolerance to drugs targeting the cell wall. Central to the core of this
signaling cascade is Pkc1, the sole PKC isoenzyme in S. cerevisiae
that is essential under standard growth conditions and regulates
maintenance of cell wall integrity during growth, morphogenesis,
and response to cell wall stress [28,29,30,31]. Signals are initiated
by a family of cell surface sensors that are coupled to the small G-
protein Rho1, which activates a set of effectors including Pkc1.
Pkc1 signaling has been the focus of extensive study in S. cerevisiae
where it is known to regulate multiple targets, most notably the
mitogen-activated protein kinase (MAPK) cascade comprised of a
linear series of protein kinases including the MAPKKK Bck1, the
MAPKKs Mkk1/2, and the MAPK Slt2 that relays signals to the
terminal transcription factors Rlm1 and Swi4/Swi6. While Pkc1 is
not essential in C. albicans [32], the Pkc1-activated MAPK cascade
is conserved in C. albicans with Bck1, Mkk2, and the Slt2 homolog
Mkc1 [33]. In both species, components of the Pkc1 signaling
cascade have been implicated in mediating tolerance to the stress
exerted by the echinocandins that target the fungal cell wall
[34,35,36,37].
Here, we embarked on a drug screen of 1,280 pharmacolog-
ically active compounds to identify molecules that abrogate azole
resistance of both an S. cerevisiae resistant mutant and a C. albicans
clinical isolate. We identified a key role for PKC signaling in
mediating crucial responses to azoles as well as to other drugs
targeting the ergosterol biosynthesis pathway, including allyl-
amines and morpholines. Pkc1 regulated responses to azoles at
least in part via the MAPK cascade in both species via multiple
downstream effectors. Strikingly, inhibition of Pkc1 function
phenocopied inhibition of Hsp90 or calcineurin. In S. cerevisiae,
compromise of PKC signaling blocked calcineurin activation in
response to ergosterol biosynthesis inhibitors, providing a
compelling mechanism for the impact on drug resistance. In C.
albicans, we found that Pkc1 and calcineurin independently
regulate resistance via a common target. The complexity of
interactions linking PKC signaling, Hsp90, and calcineurin was
further illuminated as genetic reduction of C. albicans Hsp90
resulted in destabilization of Mkc1 thereby blocking its activation.
Deletion of C. albicans PKC1 rendered the fungistatic ergosterol
biosynthesis inhibitors fungicidal and attenuated virulence in a
murine model of systemic disease. Our findings establish an
Author Summary
Treating fungal infections is challenging due to the
emergence of drug resistance and the limited number of
clinically useful antifungal drugs. We screened a library of
1,280 pharmacologically active compounds to identify
those that reverse resistance of the leading human fungal
pathogen, Candida albicans, to the most widely used
antifungals, the azoles. This revealed a new role for protein
kinase C (PKC) signaling in resistance to drugs targeting
the cell membrane, including azoles, allylamines, and
morpholines. We dissected mechanisms through which
PKC regulates resistance in C. albicans and the model yeast
Saccharomyces cerevisiae. PKC enabled survival of cell
membrane stress at least in part through the mitogen-
activated protein kinase (MAPK) cascade in both species. In
S. cerevisiae, inhibition of PKC signaling blocked activation
of a key regulator of membrane stress responses,
calcineurin. In C. albicans, Pkc1 and calcineurin indepen-
dently regulate resistance via a common target. Deletion
of C. albicans PKC1 rendered fungistatic drugs fungicidal
and reduced virulence in a mouse model. The molecular
chaperone Hsp90, which stabilizes client proteins includ-
ing calcineurin, also stabilized the terminal C. albicans
MAPK, Mkc1. We establish new circuitry connecting PKC
with Hsp90 and calcineurin and suggest a promising
strategy for treating life-threatening fungal infections.
PKC Regulates Fungal Drug Resistance and Virulence
PLoS Pathogens | www.plospathogens.org 2 August 2010 | Volume 6 | Issue 8 | e1001069entirely new role for PKC signaling in basal tolerance and
resistance to ergosterol biosynthesis inhibitors, a novel mechanism
through which Hsp90 regulates drug resistance, and that targeting
Pkc1 provides a promising therapeutic strategy for life-threatening
fungal infections.
Results
A screen of 1,280 pharmacologically active compounds
identifies hits that abrogate azole resistance
To identify compounds that enhance the efficacy of the azole
fluconazole we screened the LOPAC
1280 Navigator library. Our
initial screen used an S. cerevisiae strain with azole resistance due to
deletion of ERG3. This resistance phenotype is exquisitely sensitive
to perturbation of stress response pathways [24,25]. To enhance
the activity of library compounds, this azole-resistant mutant also
harbored deletion of PDR1 and PDR3, transcription factors that
regulate the expression of numerous multidrug transporters which
efflux structurally diverse compounds from the cell [38]. The
library was initially screened at 25 mM in defined RPMI medium
at 30uC in the presence of 8 mg/ml fluconazole, which reduces
growth of this strain by less than 50% . The compounds that
reduced growth by greater than or equal to 50% relative to the
fluconazole-only controls were re-screened at 12.5 mM in the
presence and absence of fluconazole to distinguish those that
enhance the activity of fluconazole from those that are simply toxic
on their own. This screen identified 185 compounds that
enhanced the efficacy of fluconazole (data not shown). To
prioritize compounds with synergistic activity with fluconazole
against a clinical isolate of C. albicans, we then screened the 185
compounds at 12.5 mM for activity against an isolate from an
HIV-infected patient undergoing fluconazole treatment, both in
the presence and absence of fluconazole at 8 mg/ml. The capacity
of this clinical isolate to grow in the presence of high
concentrations of azole is critically dependent upon cellular stress
responses [25], despite the fact that it has increased expression of
the multidrug transporter Mdr1 relative to a drug-sensitive isolate
recovered from the same patient at an earlier time point
[39,40,41]. This secondary screen identified seven compounds
that had little toxicity on their own but which enhanced the
efficacy of fluconazole (Figure 1A). One hit from our screen,
brefeldin A, was recently confirmed to exhibit potent synergy with
antifungals against Candida and Aspergillus [42]. Strikingly, three of
the seven hits were characterized as inhibitors of protein kinase C
(PKC).
Pharmacological inhibition of PKC enhances the efficacy
of antifungal drugs targeting the cell membrane
PKC governs the cell wall integrity signaling pathway so named
for its role in regulating cell wall integrity during growth,
morphogenesis, and exposure to stress in fungi [29,30,31]. In
both S. cerevisiae and C. albicans, the PKC signaling cascade is
known to regulate cellular responses crucial for survival of
exposure to antifungal drugs targeting the cell wall, such as the
echinocandins [34,35,36,37]. Since the PKC inhibitors identified
in our screen were characterized in mammalian cells [43,44], we
next turned to other pharmacological inhibitors of PKC whose
mode of action had been validated in fungi. Cercosporamide was
identified as a selective Pkc1 inhibitor through C. albicans Pkc1-
based high-throughput screening and was shown to exhibit potent
synergy with echinocandins [45]. We purified cercosporamide
from the fungus Cercosporidium henningsii following standard
protocols [46]. As a positive control, we tested the impact of a
concentration gradient of cercosporamide on growth in the
presence of a fixed concentration of the echinocandin micafungin
that causes less than 50% inhibition of growth on its own and
confirmed that cercosporamide had the expected synergistic
activity with micafungin against the clinical C. albicans isolate
(Figure 1B). Using a comparable assay, we determined that
cercosporamide also enhanced the activity of fluconazole
(Figure 1B), validating the results from our screen. We further
confirmed our pharmacological findings with another PKC
inhibitor characterized in fungi, staurosporine [47,48]. Both
cercosporamide and staurosporine enhanced the efficacy of
antifungals targeting the cell wall, micafungin, and those targeting
the cell membrane (Figure 1C), including fluconazole and the
morpholine fenpropimorph, which inhibits Erg2 and Erg24 [49].
While staurosporine enhanced the efficacy of another ergosterol
biosynthesis inhibitor that inhibits Erg1 [49], the allylamine
terbinafine, cercosporamide did not (Figure 1C). The lack of effect
of cercosporamide on terbinafine tolerance is likely an artifact of
an inactivating drug-drug interaction given that mutants that are
hypersensitive to terbinafine are rendered resistant by cercospor-
amide (data not shown).
Genetic validation that Pkc1 enables tolerance to drugs
that affect the cell membrane via the MAPK cascade in S.
cerevisiae
In S. cerevisiae, PKC1 is essential [50], thus we used a strain
harboring only a temperature-sensitive (ts) pkc1-3 allele [51] and
assayed tolerance to three ergosterol biosynthesis inhibitors
fluconazole, fenpropimorph, and terbinafine. Growth of the
wild-type strain and the pkc1-3 ts mutant was assayed over a
gradient of drug concentrations relative to a drug-free control at
either the permissive temperature (30uC) or at a more restrictive
temperature, but where the pkc1-3 ts mutant was still able to thrive
in the absence of antifungals (35uC). At the permissive tempera-
ture, the wild type and the pkc1-3 ts mutant had comparable
tolerance to all three drugs tested (Figure S1A). At the restrictive
temperature, the pkc1-3 ts mutant was hypersensitive to all three
drugs (Figure 2A). The same trend was observed when a dilution
series of cells was spotted on solid medium with a fixed
concentration of drug (Figure S1B). To determine if reduction of
Pkc1 function rendered the fungistatic ergosterol biosynthesis
inhibitors fungicidal we used tandem assays with an antifungal
susceptibility test performed at the restrictive temperature followed
by spotting onto rich medium without any inhibitors. The wild-
type strain was able to grow on rich medium following exposure to
all concentrations of drug tested (Figure 2B); compromise of Pkc1
function in the pkc1-3 ts mutant enhanced cidality of all three
drugs with the most severe effect for fluconazole and fenpropi-
morph. Thus, reduction of Pkc1 activity increases sensitivity to
drugs targeting the cell membrane and enhances cidality of these
otherwise fungistatic agents.
Despite the simple linear schematic commonly used to illustrate
the architecture of the Pkc1 cell wall integrity pathway (Figure 2C),
there is evidence for additional Pkc1 targets [30] and multiple
cases of cross talk with other stress response pathways [28]. We
next sought to determine if the effects of Pkc1 on tolerance to
ergosterol biosynthesis inhibitors are due to signaling via the
downstream MAPK cascade. S. cerevisiae mutants lacking the
MAPKKK Bck1 or the terminal MAPK Slt2 were hypersensitive
to all three ergosterol biosynthesis inhibitors tested in both a liquid
antifungal susceptibility assay measuring growth of a fixed
concentration of cells across a gradient of drug concentrations
(Figure 2A) and a spotting assay of a dilution of cells on solid
medium with a fixed concentration of drug (Figure S1B). Deletion
of the MAPK components also rendered these fungistatic drugs
PKC Regulates Fungal Drug Resistance and Virulence
PLoS Pathogens | www.plospathogens.org 3 August 2010 | Volume 6 | Issue 8 | e1001069Figure 1. Pharmacological inhibition of PKC signaling enhances the efficacy of antifungal drugs targeting the cell membrane. (A)A
drug screen identifies compounds that abrogate fluconazole (FL) resistance of a Candida albicans clinical isolate (CaCi-2). Seven compounds from the
LOPAC
1280 Navigator library had little toxicity on their own but enhanced the efficacy of FL against CaCi-2 when tested at 12.5 mM in RPMI medium
with 2% glucose in the presence or absence of 8 mg/ml FL. Growth was measured by absorbance at 600 nm after 48 hours at 30uC. Optical densities
were averaged for duplicate measurements and normalized relative to the no compound control (-) or FL-only control. Data was quantitatively
displayed with colour using Treeview (see colour bar). The target or mode of action of each compound is indicated in blue.
1CAT=choline
acetyltransferase;
2JAK3=Janus kinase family protein; and
3KDO-8-P=3-deoxy-D-manno-2-octulosonate-8-phosphate. (B) Pharmacological inhibition
of Pkc1 with cercosporamide abrogates azole resistance and reduces echinocandin tolerance of CaCi-2 in an MIC assay. Assays were done in yeast
peptone dextrose (YPD) with a fixed concentration of 2 mg/ml micafungin (MF) or 8 mg/ml FL, as indicated. Data was analyzed after 48 hours at 30uC
as in part A. (C) Pkc1 inhibitors confer increased sensitivity to other ergosterol biosynthesis inhibitors. A fixed concentration of CaCi-2 cells was
incubated in YPD with no antifungal (-), 2 mg/ml MF, 8 mg/ml FL, 2.5 mg/ml fenpropimorph (FN), or 2 mg/ml terbinafine (TB) and with the PKC
inhibitors cercosporamide (100 mg/ml) or staurosporine (37.5 ng/ml), as indicated. Data was analyzed after 48 hours at 30uC as in part A.
doi:10.1371/journal.ppat.1001069.g001
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inhibitors via the MAPK cascade in S. cerevisiae.
Pkc1 enables tolerance to drugs that affect the cell
membrane in part via the MAPK cascade in C. albicans
In C. albicans, PKC1 is not essential though it does share a high
degree of sequence conservation with S. cerevisiae PKC1 and has a
conserved role in regulating cell wall integrity through a conserved
MAPK cascade [32,33]. To genetically validate the role of C.
albicans PKC1 in tolerance to drugs affecting the cell membrane, we
constructed a pkc1D/pkc1D mutant. Homozygous deletion of PKC1
rendered the strain hypersensitive to all three ergosterol biosyn-
thesis inhibitors tested in liquid static susceptibility assays
(Figure 3A) as well as on solid medium (Figure S2A). Comparable
results were obtained in well-aerated shaking liquid cultures (data
not shown). Restoring a wild-type PKC1 allele under the control of
the native promoter to the native locus restored drug tolerance
(Figure S2). To determine if deletion of C. albicans PKC1 renders
the ergosterol biosynthesis inhibitors fungicidal, we used tandem
assays with an antifungal susceptibility test followed by spotting
onto rich medium without inhibitor. A strain with wild-type PKC1
levels was able to grow on rich medium following exposure to all
drug concentrations tested (Figure 3B). Homozygous deletion of C.
albicans PKC1 was cidal in combination with any dose of ergosterol
biosynthesis inhibitor tested; no cells were able to grow on rich
medium following exposure to the treatments. Thus, Pkc1
Figure 2. Pkc1 enables basal tolerance to ergosterol biosynthesis inhibitors via the MAPK cascade in Saccharomyces cerevisiae. (A)
Drug tolerance of a wild-type (WT) strain (BY4741), a derivative (pkc1-ts) with a temperature sensitive PKC1 allele, and derivatives with deletions of
BCK1 and SLT2 are compared in MIC assays. Assays were performed in synthetic defined (SD) medium at 35uC. Data was analyzed after 48 hours as in
Figure 1A. The minimum drug concentration that inhibits growth by 80% relative to the drug-free growth control (MIC80) is indicated for each strain.
(B) Genetic compromise of Pkc1 creates a fungicidal combination with ergosterol biosynthesis inhibitors. MIC assays with two-fold dilutions of
fluconazole (FL), fenpropimorph (FN), and terbinafine (TB) were performed in SD and incubated for 48 hours at 35uC. Cells from the MIC assays were
spotted onto YPD medium and incubated at 30uC for 48 hours before plates were photographed. (C) Schematic of the S. cerevisiae Pkc1 cell wall
integrity pathway.
doi:10.1371/journal.ppat.1001069.g002
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stress exerted by antifungal drugs.
As an initial approach to assess whether the MAPK cascade was
implicated in responses to drugs targeting the cell membrane, we
monitored activation of the terminal MAPK in C. albicans. Mkc1 is
known to be activated in response to distinct stress conditions
including oxidative stress, changes in osmotic pressure, cell wall
damage, and cell membrane perturbation [52]. To determine if
Mkc1 is activated in response to ergosterol biosynthesis inhibitors
we monitored Mkc1 phosphorylation using an antibody that detects
dual phosphorylation on conserved threonine and tyrosine residues.
Exposure to fluconazole, fenpropimorph, and terbinafine led to
Mkc1 activation comparable to exposure to the cell wall damaging
antifungal micafungin (Figure S3A). However, activation of signal
transducers is not always coupled with functional consequences of
their deletion. For example, Mkc1 is activated by exposure to
hydrogen peroxide but is not required for survival of this stress [52].
To determine if the role of the MAPK cascade was conserved in
C. albicans, we constructed homozygous deletion mutants lacking
either the MAPKKK Bck1 or the terminal MAPK Mkc1 (homolog
of S. cerevisiae Slt2). Homozygous deletion of either BCK1 or MKC1
rendered strains hypersensitive to fluconazole, fenpropimorph, and
terbinafine (Figure 3A) but had negligible effect at elevated
temperatures (Figure S3B). This stands in contrast to our results
with S. cerevisiae that demonstrated an equivalent role of the MAPK
cascade at all temperatures tested (Figure 2, Figure S1 and S4).
While deletion of C. albicans PKC1 rendered the ergosterol
biosynthesis inhibitors fungicidal, deletion of BCK1 or MKC1 did
not (Figure 3B). These results not only implicate the MAPK cascade
in C. albicans but also suggest that alternate effectors downstream of
Pkc1 are more important at elevated temperature and enable
survival in the presence of ergosterol biosynthesis inhibitors.
The role of targets downstream of the terminal MAPK in
tolerance to ergosterol biosynthesis inhibitors
Effectors downstream of the terminal MAPK of the PKC
signaling cascade have been well studied in S. cerevisiae and include
Figure 3. Pkc1 enables basal tolerance to ergosterol biosynthesis inhibitors in part via the MAPK cascade in Candida albicans. (A)
Deletion of PKC1, BCK1 or MKC1 reduces tolerance to fluconazole (FL), fenpropimorph (FN), and terbinafine (TB) in MIC assays. Assays were performed
in YPD medium at 35uC with strains derived from the WT SN95. Data was analyzed after 72 hours growth as in Figure 1A. The minimum drug
concentration that inhibits growth by 80% relative to the drug-free growth control (MIC80) is indicated for each strain. (B) Deletion of PKC1, but not
MAPK components, creates a fungicidal combination with the ergosterol biosynthesis inhibitors in C. albicans. MIC assays with four-fold dilutions of
FL, FN, and TB were performed in YPD and incubated for 48 hours at 35uC. Cells from the MIC assays were spotted onto YPD medium and incubated
at 30uC for 48 hours before plates were photographed.
doi:10.1371/journal.ppat.1001069.g003
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activation of two transcription factors Rlm1 and SBF, which is
comprised of Swi4 and Swi6 [30]. Rlm1 mediates the majority of
the transcriptional output of cell wall integrity signaling, largely
genes involved in cell wall biogenesis [53]. SBF drives cell cycle-
specific transcription and is also regulated by Slt2 in response to
cell wall stress (reviewed in [30]). Swi4 interacts directly with Slt2
and has additional roles in transcriptional regulation independent
of the regulatory subunit Swi6 [54]. Slt2 translocates from the
nucleus to the cytoplasm in response to cell wall stress [55].
Cytoplasmic Slt2 is required for activation of a high-affinity Ca
2+
influx system in the plasma membrane that is comprised of two
subunits, Cch1 and Mid1, in response to endoplasmic reticulum
stress [56]. Activation of the Cch1-Mid1 channel leads to the
accumulation of intracellular Ca
2+ and activation of the protein
phosphatase calcineurin [57].
To dissect the role of downstream effectors of Slt2 in ergosterol
biosynthesis inhibitor tolerance, we tested the impact of their
deletion individually and in combination on antifungal suscepti-
bility. For reference, we included a strain lacking the regulatory
subunit of calcineurin, CNB1, which is hypersensitive to ergosterol
biosynthesis inhibitors [24]. For fluconazole, deletion of RLM1,
CCH1,o rMID1 had negligible impact on tolerance while deletion
of SWI4 or SWI6 rendered strains almost as sensitive as the slt2D
mutant (Figure 4). To determine if there was redundancy among
the downstream effectors, we constructed strains harboring
deletion of multiple effectors. Deletion of CCH1 phenocopies
deletion of the entire channel and deletion of SWI4 abolishes SBF
function as well as Swi4-dependent transcription independent of
SBF. Thus, combined deletion of CCH1, SWI4, and RLM1 should
eliminate the four known targets of Slt2 phosphorylation. No
additional increase in sensitivity was observed in double or triple
mutants. This suggests that the SBF transcription factor is of
central importance for enabling responses to fluconazole. For
fenpropimorph, deletion of RLM1, CCH1,o rMID1 had no impact
on tolerance individually while deletion of SWI4 or SWI6 caused a
partial increase in sensitivity (Figure 4). Deletion of RLM1 in the
context of the swi4D or swi6D mutants further increased
fenpropimorph sensitivity. Deletion of CCH1 in the mutant
backgrounds had little additional impact. This suggests that SBF
is the major determinant of fenpropimorph tolerance with RLM1
enabling additional responses important in the absence of SBF.
For tolerance to terbinafine, deletion of RLM1 had no impact
while deletion of SWI4 caused a partial increase in sensitivity
(Figure 4). Unlike tolerance to fluconazole and fenpropimorph,
deletion of SWI6 had negligible impact on terbinafine tolerance
while deletion of CCH1 or MID1 caused a partial increase in
sensitivity. Deletion of both RLM1 and CCH1 in the swi4D mutant
caused an incremental increase in sensitivity (Figure 4). These
results suggest that Swi4 enables terbinafine tolerance independent
of the SBF complex and that Rlm1 and Cch1 mediate responses
that are important in the absence of Swi4. Thus, distinct
downstream effectors are important for tolerance of S. cerevisiae
to different ergosterol biosynthesis inhibitors.
Next, we tested a set of C. albicans mutants to determine if the
role of the effectors downstream of the terminal MAPK of the
PKC signaling cascade was conserved. As was the case with S.
cerevisiae, deletion of RLM1 on its own had no impact on tolerance
to the ergosterol biosynthesis inhibitors (Figure 5), consistent with
recent findings [58]. Deletion of SWI4 rendered strains hypersen-
sitive to all three ergosterol biosynthesis inhibitors tested (Figure 5).
Deletion of SWI6 or combined deletion of both SWI4 and SWI6
conferred a comparable increase in sensitivity (data not shown;
unpublished strains generously provided by Catherine Bachewich),
implicating the SBF complex in responses to drug-induced
membrane stress. Deletion of CCH1 or MID1 individually or in
combination had a comparable effect to deletion of SWI4
rendering the strain hypersensitive to all three ergosterol
biosynthesis inhibitors tested (Figure 5). Notably, C. albicans
cch1D/cch1D and mid1D/mid1D mutants share some but not all
phenotypes of a calcineurin mutant [59]. In terms of ergosterol
biosynthesis inhibitor sensitivity, deletion of the gene encoding the
catalytic subunit of calcineurin, CNA1, caused hypersensitivity akin
to that of the cch1D/cch1D and mid1D/mid1D mutants for
fluconazole and fenpropimorph but caused slightly greater
sensitivity to terbinafine (Figure 5). Thus, in C. albicans both the
SBF complex and the Cch1-Mid1 channel play critical roles in
tolerance to drugs that target the cell membrane.
PKC signaling enables calcineurin activation in response
to ergosterol biosynthesis inhibitors via a mechanism
distinct from Cch1-Mid1 in S. cerevisiae
Given calcineurin’s established role in mediating drug-induced
membrane stress responses [24,25,57] and that Slt2 has been
shown to enable calcineurin activation by phosphorylating Cch1
[56], we tested whether calcineurin was activated in response to
ergosterol biosynthesis inhibitors and whether deletion of Slt2
blocked this activation. To monitor calcineurin activation, we used
a well-established reporter system that exploits the downstream
effector Crz1, a transcription factor that is dephosphorylated upon
calcineurin activation [60,61]. Dephosphorylated Crz1 translo-
cates to the nucleus, driving expression of genes with calcineurin-
dependent response elements (CDREs) in their promoters. We
used a reporter containing four tandem copies of CDRE and a
CYC1 minimal promoter driving lacZ [61]. We confirmed previous
findings that fluconazole activates calcineurin ([27,62] and
Figure 6A). We also found that the other ergosterol biosynthesis
inhibitors terbinafine and fenpropimorph activate calcineurin
(P,0.001, ANOVA, Bonferroni’s Multiple Comparison Test,
Figure 6A). Deletion of SLT2 completely blocked calcineurin
activation in response to ergosterol biosynthesis inhibitors as did
deletion of the regulatory subunit of calcineurin required for its
activation, encoded by CNB1 (P,0.001). Pharmacological inhibi-
tion of PKC signaling with staurosporine also blocked calcineurin
activation (P,0.001, Figure 6B). The block in calcineurin
activation was not an artifact of compromised viability as
treatment conditions were optimized such that all cultures
underwent comparable growth with equivalent protein yields.
Given that the slt2D mutant is slightly more sensitive to ergosterol
biosynthesis inhibitors than the mutant lacking calcineurin
function, it is likely that Slt2 regulates responses to ergosterol
biosynthesis inhibitors through additional targets. The swi4D
mutant is less sensitive than the calcineurin mutant, suggesting that
Slt2 regulates calcineurin function independently of Swi4 and that
Swi4 regulates ergosterol biosynthesis inhibitor tolerance through
additional targets (Figure 6C).
Given that deletion of CCH1 and MID1 had negligible effect on
tolerance to fluconazole or fenpropimorph and only an interme-
diate effect on tolerance to terbinafine, it is likely that compromise
of PKC signaling blocked calcineurin activation by a mechanism
that is largely distinct from the Cch1-Mid1 channel. One possible
mechanism is that the effects are transcriptional and mediated
through a nuclear target of Slt2 such that inhibition of PKC
signaling compromises the expression of calcineurin or CRZ1.
However, deletion of SLT2 did not reduce the expression of genes
encoding any of the calcineurin subunits (CNA1, CNA2 or CNB1)
or CRZ1 as measured by quantitative RT-PCR in the presence or
absence of ergosterol biosynthesis inhibitor (P.0.05, ANOVA,
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PLoS Pathogens | www.plospathogens.org 7 August 2010 | Volume 6 | Issue 8 | e1001069Figure 4. Distinct downstream effectors are important for tolerance of S. cerevisiae to different ergosterol biosynthesis inhibitors. To
dissect the role of downstream effectors of Slt2 in tolerance to ergosterol biosynthesis inhibitors, we tested the impact of their deletion individually
and in combination on drug susceptibility in an MIC assay. Data was analyzed after 72 hours at 35uC in SD medium as in Figure 1A. The minimum
drug concentration that inhibits growth by 80% relative to the drug-free growth control (MIC80) is indicated for each strain.
doi:10.1371/journal.ppat.1001069.g004
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signaling enables calcineurin activation in response to ergosterol
biosynthesis inhibitors by a mechanism that is largely distinct from
the Cch1-Mid1 channel or transcriptional control of calcineurin.
PKC signaling and calcineurin independently regulate
tolerance to ergosterol biosynthesis inhibitors via a
common target in C. albicans
In contrast to the minor impact of deletion of the S. cerevisiae
Cch1-Mid1 channel, deletion of the C. albicans Cch1-Mid1
channel had nearly as great an effect as deletion of the catalytic
subunit of calcineurin in response to fluconazole and fenpropi-
morph; for terbinafine the effect was partial (Figure 5). To test if
the ergosterol biosynthesis inhibitors activate calcineurin and if
inhibition of PKC signaling blocks this activation, we monitored
transcript levels of two calcineurin-dependent genes, PLC3 and
UTR2 [63]. In a wild-type strain, fluconazole activated calcineurin
as measured by an increase in PLC3 and UTR2 transcript levels
(P,0.05, ANOVA, Bonferroni’s Multiple Comparison Test,
Figure 7A). As expected, deletion of the catalytic subunit of
calcineurin, CNA1, blocked the induction of PLC3 and UTR2
transcripts (P,0.01). Deletion of PKC1 did not block induction of
PLC3 or UTR2 indicating that impairment of PKC signaling does
not block calcineurin activation (Figure 7A). At 35uC, conditions
under which Pkc1 downstream effectors other than the MAPK
cascade are more important in tolerance to ergosterol biosynthesis
inhibitors, deletion of PKC1 increased the magnitude of induction
of PLC3 and UTR2 (P,0.001, Figure 7A). At 30uC, conditions
under which the MAPK cascade mediates tolerance to ergosterol
biosynthesis inhibitors, deletion of PKC1 had no significant impact
on calcineurin-dependent transcription (data not shown). Thus,
drugs that inhibit ergosterol biosynthesis induce calcineurin
activation in a manner that is independent of PKC signaling.
Next, we addressed alternative models that could explain the
relationship between PKC signaling and calcineurin in C. albicans
tolerance to ergosterol biosynthesis inhibitors. One possible model
Figure 5. Swi4 and Cch1-Mid1 play critical roles in ergosterol biosynthesis inhibitor tolerance of C. albicans. Deletion of SWI4 or
components of the Cch1-Mid1 channel confer increased sensitivity to the ergosterol biosynthesis inhibitors in a MIC assay. Deletion of Rlm1 had no
impact on drug sensitivity. A strain lacking the catalytic subunit of calcineurin (Cna1) is included for reference. Data was analyzed after 48 hours in
YPD at 35uC as in Figure 1A. The minimum drug concentration that inhibits growth by 80% relative to the drug-free growth control (MIC80)i s
indicated for each strain.
doi:10.1371/journal.ppat.1001069.g005
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PLoS Pathogens | www.plospathogens.org 9 August 2010 | Volume 6 | Issue 8 | e1001069Figure 6. Compromising PKC-MAPK signaling blocks calcineurin activation in response to ergosterol biosynthesis inhibitors in S.
cerevisiae. (A) Genetically compromising PKC-MAPK signaling by deleting SLT2 blocks calcineurin activation monitored with a 4XCDRE-lacZ reporter.
b-galactosidase activity was measured after incubation in SD medium for 24 hours without any antifungal (U) or in the presence of ergosterol
biosynthesis inhibitors at the following concentrations: 16 mg/mL fluconazole (FL), 1 mg/mL fenpropimorph (FN), or 25 mg/mL terbinafine (TB). While
the WT strain exhibited increased b-galactosidase activity in response to ergosterol biosynthesis inhibitors, deletion of SLT2 or CNB1 (which encodes
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non-redundant pathways. This model leads to two predictions for
ergosterol biosynthesis inhibitor tolerance: 1) there should be a
synergistic effect of inhibiting both pathways simultaneously and 2)
compromise of one pathway should confer increased sensitivity to
inhibition of the other. To test the first prediction, we performed
checkerboard assays in which a wild-type strain was exposed to a
uniform concentration of fluconazole and a concentration gradient
of both the calcineurin inhibitor cyclosporin A and the Pkc1
inhibitor staurosporine. There was no obvious synergy detected
upon inhibition of both pathways in combination with fluconazole
(Figure 7B). To assess this quantitatively we calculated the
standard index of drug synergy, the fractional inhibitory
concentration (FIC). The FIC value was 0.75 confirming that
there was no synergy. To test the second prediction, we measured
the impact of Pkc1 inhibition on fluconazole tolerance of a mutant
lacking the catalytic subunit of calcineurin, CNA1. Growth of the
cna1D/cna1D mutant was assessed in the absence or presence of
the highest concentration of fluconazole that it could tolerate and
with a gradient of the Pkc1 inhibitor cercosporamide. Fluconazole-
sensitivity of the cna1D/cna1D mutant was not affected by
cercosporamide (Figure 7C). The reciprocal was also true, such
that the pkc1D/pkc1D mutant was not rendered hypersensitive to
fluconazole by the calcineurin inhibitor cyclosporin A (data not
shown). Thus, our results do not support either prediction of the
model in which Pkc1 and calcineurin regulate ergosterol
biosynthesis inhibitor tolerance through parallel pathways. We
also ruled out the possibility that inhibition of calcineurin blocks
PKC signaling as measured by levels of activated Mkc1 (data not
shown). Taken together, these findings support a model in which
Pkc1 and calcineurin independently regulate crucial responses to
ergosterol biosynthesis inhibitors through a common target
(Figure 7D). This target is not Crz1, the only well-characterized
effector downstream of C. albicans calcineurin, given that
transcription of the calcineurin-dependent genes PLC3 and
UTR2 is mediated through the transcription factor Crz1 [63].
Inhibition of PKC signaling phenocopies inhibition of
Hsp90 reducing azole resistance of C. albicans clinical
isolates and resistant mutants
To determine if the role of PKC signaling in tolerance to drugs
targeting the cell membrane was conserved in the context of bona
fide drug resistance, we turned to C. albicans clinical isolates and
resistant mutants (Figure 8). We tested the impact of two
structurally unrelated Pkc1 inhibitors, cercosporamide and
staurosporine, on azole susceptibility of a series of C. albicans
isolates that evolved fluconazole resistance in a human host [40].
The isolates shown begin with the second isolate in the series,
which is the first with elevated resistance and increased expression
of the multidrug transporter Mdr1 [39,40,41]. Azole resistance of
this series is known to have evolved from a state of dependence on
calcineurin and Hsp90 to a state of independence and this change
is associated with the accumulation of additional mutations [25].
The third isolate from the bottom (Figure 8A) has mutation
(R467K) and increased expression of the azole target Erg11; the
last two isolates, which show the least of effect of Hsp90 inhibition
on resistance, also have increased expression of the multidrug
transporter Cdr1 [39,40,41]. Inhibition of Pkc1 had a strikingly
similar impact on azole resistance to inhibition of Hsp90 or
calcineurin, reducing resistance of isolates recovered early during
treatment to a greater extent than those recovered late during
treatment (Figure 8A).
To further explore the relationship between stress response
signaling and classic resistance mechanisms such as mutation of
the drug target and overexpression of multidrug transporters, we
characterized additional clinical isolates and laboratory-derived
mutants. We tested an additional five sets of clinical isolates for
which we had one isolate recovered early during azole treatment
and one recovered later. In all cases, inhibition of Pkc1
phenocopied inhibition of Hsp90, with the least effect on azole
resistance of isolates that overexpressed the multidrug transporter
Cdr1 (Figure S6). Since the clinical isolates often harbor multiple
mechanisms of resistance, we also tested specific laboratory-
derived resistant mutants. Inhibition of Pkc1 abolished resistance
of laboratory-derived C. albicans and S. cerevisiae erg3 loss-of-function
mutants (Figure 8B), as does inhibition of Hsp90 or calcineurin
[24,25]. In contrast, inhibition of Pkc1 did not affect S. cerevisiae
resistance due to an activating mutation in the transcription factor
Pdr1 that causes overexpression of multidrug transporters
including Pdr5 (Figure 8B), as was the case with inhibition of
Hsp90 [25]. We previously confirmed that genetic compromise of
Hsp90 function does not affect resistance due to overexpression of
Pdr5, confirming that the stability of this resistance phenotype is
not due to Hsp90 inhibitors being pumped out of the cell [25].
Given the equivalent impact on azole resistance of Pkc1 inhibitors
and Hsp90 inhibitors with diverse mutants, this strongly suggests
that the stability of resistance of the Pdr1 mutant cannot be
attributed to Pkc1 inhibitors being pumped out of the cell. Thus,
inhibition of PKC signaling phenocopies inhibition of Hsp90 or its
client protein calcineurin, reducing resistance of clinical isolates
and specific resistant mutants. These results are consistent with the
circuitry connecting PKC signaling and calcineurin delineated
above and may also suggest an additional functional connection
between Hsp90 and PKC signaling in regulating responses to
ergosterol biosynthesis inhibitors.
Genetic depletion of Hsp90 destabilizes C. albicans Mkc1
While our findings already establish a link between PKC
signaling and calcineurin-mediated stress responses, we next
explored the possibility of yet another functional connection
between Hsp90 and PKC signaling. In S. cerevisiae, Hsp90 binds
exclusively to the activated form of Slt2 and enables Slt2-mediated
activation of the downstream target Rlm1 [64]. To determine if
the connection between Hsp90 and the terminal MAPK is
conserved in C. albicans, we tested the impact of genetic depletion
of C. albicans HSP90 on Mkc1 levels and activation status. To
deplete Hsp90, we used a strain with its only HSP90 allele under
the control of a doxycycline repressible promoter [65]. To monitor
total Mkc1 levels, this kinase was tagged at the C-terminus using a
6x-histidine and FLAG epitope tag. The Mkc1-6xHis-FLAG
protein was functional and sufficient to confer wild-type tolerance
to ergosterol biosynthesis inhibitors (Figure S7). To determine
the regulatory subunit of calcineurin) blocked calcineurin activation. Data are means 6 SD for triplicate samples and are representative of two
independent experiments. (B) Pharmacological inhibition of PKC signaling with staurosporine (STS) blocks calcineurin activation monitored with a
4XCDRE-lacZ reporter. b-galactosidase activity was measured after incubation in SD medium (-) or in SD with 2.5 mg/mL STS. Cells were then treated
with 32 mg/mL FL or were left untreated (U). Data are means 6 SD for triplicate samples and are representative of two independent experiments. (C)
Simplified schematic of how S. cerevisiae Pkc1 regulates responses to ergosterol biosynthesis inhibitors (EBIs) important for basal tolerance and
resistance.
doi:10.1371/journal.ppat.1001069.g006
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PLoS Pathogens | www.plospathogens.org 11 August 2010 | Volume 6 | Issue 8 | e1001069Figure 7. PKC signaling and calcineurin independently regulate tolerance to ergosterol biosynthesis inhibitors via a common
target in C. albicans. (A) Deletion of C. albicans PKC1 does not block EBI-induced activation of calcineurin. Transcript levels of two calcineurin-
dependent genes, PLC3 and UTR2, were measured by quantitative RT-PCR after growth in rich medium at 35uC for 6 hours without any antifungal (U)
or with 16 mg/mL fluconazole (FL), as indicated. Transcripts were normalized to GPD1. Levels are expressed relative to the untreated wild-type
samples, which were set to 1. Data are means 6 SD for triplicate samples and are representative of two independent experiments. (B) Simultaneous
inhibition of calcineurin and Pkc1 signaling does not synergistically decrease FL tolerance of a WT strain (SN95). A fractional inhibitory concentration
(FIC) assay was carried out in YPD medium containing a fixed concentration of 0.5 mg/mL FL and gradients of the calcineurin inhibitor cyclosporin A
(CsA) and the PKC inhibitor staurosporine (STS). Data was analyzed after growth at 35uC for 48 hours as in Figure 1A. The minimum concentration of
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used a strain lacking the upstream MAPKKK required for Mkc1
activation, Bck1. All strains were grown in the presence of
terbinafine to induce Mkc1 activation. In the absence of
doxycycline (Figure 9A, left panel), all strains had comparable
levels of Hsp90 as measured relative to a histone H3 loading
control. All strains also had comparable levels of activated dually-
phosphorylated Mkc1, with the exception of the strain lacking
Bck1 in which Mkc1 activation was blocked. Total Mkc1 levels
monitored by a 6X-histidine antibody were comparable for the
three strains harboring the tagged protein. In the presence of
doxycycline (Figure 9A, right panel), Hsp90 levels were depleted
only in the strains with the repressible promoter. Depletion of
Hsp90 resulted in a corresponding depletion of total Mkc1 levels,
even in the strain lacking Bck1 in which Mkc1 remains in the
inactivate state. Depletion of Hsp90 did not affect MKC1 transcript
levels as measured by quantitative RT-PCR (P.0.05, ANOVA,
Bonferroni’s Multiple Comparison Test, Figure S8), confirming
that the chaperone influences Mkc1 stability at the protein level.
Thus, Hsp90 stabilizes Mkc1 independent of its activation status
and thereby regulates PKC signaling, providing a new mechanism
through which Hsp90 regulates drug-induced membrane stress
responses (Figure 9B).
Deletion of C. albicans PKC1 attenuates virulence in a
murine model of systemic disease
Given that deletion of PKC1 enhances the efficacy of antifungal
drugs, we next explored the therapeutic efficacy in a well-
established murine model in which fungal inoculum is delivered by
tail vein injection and progresses from the bloodstream to deep-
seated infection of major organs, most notably the kidney
[27,65,66]. We compared kidney fungal burden of mice infected
with either a wild-type strain or a pkc1D/pkc1D mutant. The
average kidney fungal burden in mice infected with 1610
5 CFUs
of the wild-type parental strain was 4.34+/20.54 log CFU per
gram of kidney (Figure 10A). In stark contrast, the kidneys of mice
infected with 1610
5 CFUs of the pkc1D/pkc1D mutant were sterile
(Figure 10A). To determine if infection with higher inocula of the
pkc1D/pkc1D mutant would lead to sufficient kidney fungal burden
to enable assessment of antifungal efficacy in vivo, we tested the
impact of infection with 10-fold and 100-fold higher inocula. Mice
infected with 1610
6 or 1610
7 CFUs of the pkc1D/pkc1D mutant
demonstrated significantly reduced fungal burden relative to those
infected with only 1610
5 CFUs of the wild-type strain (P,0.001,
ANOVA, Bonferroni’s Multiple Comparison Test). The average
kidney fungal burden in mice infected with 1610
6 or 1610
7 cells
of the pkc1D/pkc1D mutant was 0.19+/20.66 and 0.23+/20.67
log CFU per gram of kidney, respectively. Thus, while C. albicans
PKC1 is dispensable for growth under standard conditions in vitro it
is required for proliferation and infection in a murine model,
providing evidence for a key role of this stress response regulator in
virulence. While the attenuated virulence of the pkc1D/pkc1D
mutant precluded straightforward studies to determine if compro-
mising Pkc1 enhances the efficacy of antifungal drugs in vivo,i t
provides compelling support for therapeutic potential of compro-
mising fungal Pkc1.
Given our findings that Pkc1 and calcineurin affect drug
resistance via a common target in C. albicans (Figure 7), it is
possible that Pkc1-mediated signaling may influence virulence by a
target in common with calcineurin, which is known to be required
for C. albicans virulence [67,68,69]. Calcineurin mutants are
hypersensitive to calcium present in serum and are unable to
survive transit through the bloodstream [68]. However, while a
mutant lacking the catalytic subunit of calcineurin was unable to
survive on medium containing 50% serum, the pkc1D/pkc1D
mutant exhibited only an intermediate reduction in viability and
the mkc1D/mkc1D and bck1D/bck1D mutants grew as well as the
wild type (Figure 10B). Further, the pkc1D/pkc1D mutant grew as
well as the wild-type strain in liquid serum while the calcineurin
mutant was inviable (data not shown). These results suggest that
Pkc1 exerts powerful control over C. albicans virulence by means of
targets distinct from calcineurin.
Discussion
Our results establish a new role for the PKC signal transduction
cascade in resistance to drugs targeting the cell membrane in the
model yeast S. cerevisiae and the fungal pathogen C. albicans. Three
out of seven hits from our screen of 1,280 pharmacologically active
compounds for those that abrogate azole resistance are classified as
inhibitors of PKC, suggesting a central role for this cellular
regulator in azole resistance (Figure 1). Pharmacological inhibition
of Pkc1 with two additional structurally distinct PKC inhibitors
whose mode of action has been validated in fungi or genetic
compromise of Pkc1 function enhances sensitivity to azoles as well
as other drugs targeting ergosterol biosynthesis, including
allylamines and morpholines (Figures 1, 2 and 3). Pkc1 regulates
responses to ergosterol biosynthesis inhibitors at least in part
through the MAPK cascade in both species (Figures 2 and 3). In S.
cerevisiae, signaling through the MAPK cascade is required for
calcineurin activation suggesting that PKC signaling regulates
crucial responses to ergosterol biosynthesis inhibitors through
calcineurin in this species (Figure 6). In C. albicans, Pkc1 and
calcineurin independently regulate responses to ergosterol biosyn-
thesis inhibitors via a common target (Figure 7). Inhibition of Pkc1
phenocopies inhibition of calcineurin or Hsp90, reducing drug
resistance of clinical isolates of C. albicans (Figure 8 and S6). We
establish an additional level of regulatory complexity in the cellular
circuitry linking PKC signaling, Hsp90, and calcineurin in that
genetic reduction of C. albicans Hsp90 results in destabilization of
the terminal MAPK, Mkc1, thereby blocking PKC signaling
(Figure 9). This suggests that Hsp90 regulates basal tolerance and
resistance to ergosterol biosynthesis inhibitors through Mkc1 in
addition to the established connection with calcineurin. Our
findings that compromising Pkc1 renders fungistatic drugs
fungicidal (Figures 2 and 3) and attenuates virulence of C. albicans
(Figure 10) suggest broad therapeutic potential.
The role of PKC signaling in basal tolerance and resistance to
drugs targeting the cell membrane expands the repertoire of stress
responses that depend upon this signal transduction cascade. In S.
cerevisiae, it was previously appreciated that PKC signaling is
required for basal tolerance to echinocandins, which target cell
wall synthesis [35,36]. This tolerance requires activation of the
terminal MAPK Slt2 to drive Rlm1-dependent transcription of cell
wall genes [36]. In C. albicans, the PKC pathway is activated by
diverse stresses [52] and works in concert with calcineurin and the
STS or CsA that inhibits growth by 80% relative to the FL-only growth control (MIC80) individually or in combination is indicated along with the FIC.
(C) FL tolerance of a mutant lacking the catalytic subunit of calcineurin is not sensitive to inhibition of PKC signaling. MIC assays were performed in
YPD medium only (-) or YPD with a fixed concentration of 0.5 mg/mL FL. (D) Simplified schematic of how C. albicans Pkc1 regulates responses to
ergosterol biosynthesis inhibitors (EBIs) important for basal tolerance and resistance.
doi:10.1371/journal.ppat.1001069.g007
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PLoS Pathogens | www.plospathogens.org 13 August 2010 | Volume 6 | Issue 8 | e1001069Figure 8. Inhibition of PKC signaling phenocopies inhibition of Hsp90 reducing azole resistance. (A) Fluconazole (FL) resistance of
clinical isolates is abrogated by inhibition of Hsp90 or Pkc1. MIC assays were conducted in YPD medium with no inhibitor (-), with the Hsp90 inhibitor
geldanamycin (5 mM), or with the Pkc1 inhibitors cercosporamide (12.5 mg/ml) or staurosporine (0.5 mg/ml). Clinical isolates (CaCi) are ordered
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which can enhance tolerance to echinocandins [37,70]. As is the
case with drugs compromising cell wall integrity, drugs targeting
the cell membrane activate the terminal MAPK in the PKC
cascade (Figure S3A). The role of PKC signaling in tolerance to
drugs targeting the cell wall and the cell membrane raises the
possibility that induction of cell membrane stress by ergosterol
biosynthesis inhibitors could induce cell wall stress indirectly. This
is consistent with the thought that the sensors involved in PKC cell
wall integrity signaling are receptors that respond to changes in the
structure of the cell membrane [71]. Despite the commonalities,
the downstream regulation mediating responses to these different
stresses diverge. Response to cell wall stress is largely dependent on
the transcription factor Rlm1 [36], while regulation of cell
membrane stress responses is largely independent of Rlm1. In S.
cerevisiae, distinct downstream effectors contribute to tolerance to
different ergosterol biosynthesis inhibitors (Figure 4). For flucon-
azole, the SBF transcription factor (Swi4/Swi6) is of central
importance. For fenpropimorph, the SBF complex again is a
major determinant with Rlm1 enabling responses important in the
absence of SBF. For terbinafine, Swi4 enables tolerance largely
independent of SBF and Rlm1 and Cch1-Mid1 mediate responses
important in the absence of Swi4. These differences may be due to
ergosterol depletion combined with the specific sterol that
accumulates when ergosterol biosynthesis is inhibited at different
points. In C. albicans, SBF and Cch1-Mid1 confer tolerance to all
three ergosterol biosynthesis inhibitors tested suggesting that the
point of inhibition of ergosterol biosynthesis has less impact than
for S. cerevisiae.
The circuitry downstream of Pkc1 mediating membrane stress
responses has been rewired considerably between S. cerevisiae and
C. albicans. For S. cerevisiae, deletion of components of the MAPK
cascade confers hypersensitivity to ergosterol biosynthesis inhibi-
tors at all temperatures tested (Figure 2 and Figures S1 and S4).
For C. albicans, deletion of components of the MAPK cascade
confers hypersensitivity to ergosterol biosynthesis inhibitors at
30uC (Figure 3) but not at 35uC (Figure S3B), suggesting that the
MAPK cascade is a key mediator of Pkc1-dependent cell
membrane stress responses but that alternate downstream effectors
play a dominant role in C. albicans at elevated temperature. The
importance of alternate downstream effectors of Pkc1 in C. albicans
is further emphasized as deletion of PKC1 renders fungistatic
ergosterol biosynthesis inhibitors fungicidal, while deletion of
MAPK components does not (Figure 3B). Our findings highlight
another divergence between the two species. While inhibition of
PKC signaling blocks calcineurin activation in response to
ergosterol biosynthesis inhibitors in S. cerevisiae (Figure 6), this is
not the case in C. albicans. Rather, our results suggest that Pkc1 and
calcineurin independently regulate responses to ergosterol biosyn-
thesis inhibitors via a common target in C. albicans (Figure 7). As
with PKC signaling, calcineurin and Hsp90 regulate resistance to
drugs targeting the cell membrane in both C. albicans and S.
cerevisiae, however, they regulate responses to echinocandins in C.
albicans but not S. cerevisiae [27,66], suggesting both conservation
and divergence in circuitry governing fungal drug resistance.
The cellular circuitry linking PKC signaling, Hsp90, and
calcineurin is complex with multiple levels of regulatory control.
On one level is the connection between PKC signaling and
calcineurin, which is divergent between the two species. In S.
cerevisiae, inhibition of Pkc1 blocks calcineurin activation. The
terminal MAPK Slt2 has been found to activate the Cch1-Mid1
high-affinity Ca
2+ channel in response to endoplasmic reticulum
stress, thereby enabling calcineurin activation [56]. However, we
found that deletion of this channel had little impact on drug
tolerance (Figure 4), implicating calcineurin regulation via a
distinct mechanism. Since inhibition of PKC signaling does not
affect calcineurin expression (Figure S5), Slt2 likely regulates
calcineurin activation by an alternative mechanism such as
through a distinct calcium channel. In C. albicans, cch1D/cch1D
and mid1D/mid1D mutants share some but not all phenotypes with
a calcineurin mutant [59]. Consistent with this, we found that the
cch1D/cch1D and mid1D/mid1D mutants are almost as sensitive to
fluconazole and fenpropimorph as a calcineurin mutant but only
show an intermediate sensitivity to terbinafine (Figure 5). In C.
albicans, inhibition of PKC signaling did not block calcineurin
function (Figure 7). Our findings support a model in which Pkc1
and calcineurin independently regulate responses to ergosterol
biosynthesis inhibitors in C. albicans via a common target that
remains to be identified. On another level is the connection
between Hsp90 and the terminal MAPK. In S. cerevisiae, Hsp90
interacts with activated Slt2 and enables activation of Slt2 targets
including Rlm1 [64]. In C. albicans, Hsp90 stabilizes Mkc1
independent of its activation status (Figure 9). Notably, in S.
cerevisiae Hsp90 also chaperones Pkc1 [72], though this has yet to
be investigated in C. albicans. In contrast to the extensive Hsp90
network in S. cerevisiae [73,74], we identify Mkc1 as the second
Hsp90 client protein in C. albicans. Our work suggests that Hsp90
regulates responses crucial for survival of drug-induced membrane
stress through PKC signaling in addition to the established role
through calcineurin [24,25,27]. These stress responses are less
important for resistance due to overexpression of multidrug
transporters but are critical for basal tolerance as well as resistance
acquired by other diverse mutations. Future experiments will
address the relative contribution of calcineurin and PKC signaling
via the MAPK cascade in Hsp90-mediated resistance acquired by
diverse mechanisms.
Our results highlight the central importance of fungal stress
response pathways in enabling survival in the hostile host
environment. We demonstrate that while deletion of PKC1 has
little impact on growth in vitro, it drastically attenuates the capacity
of C. albicans to proliferate in vivo and cause disease (Figure 10).
While the attenuated virulence precludes studies to determine if
compromising Pkc1 enhances the efficacy of antifungals in vivo,i t
provides compelling support for targeting fungal Pkc1 as a strategy
to control fungal infections. The specific mechanism by which
Pkc1 enables virulence has yet to be determined, however, it may
operate in part via the downstream MAPK cascade given that C.
albicans Mkc1 also contributes to virulence in a murine model [75].
While Mkc1 has little impact on susceptibility to oxidative-
mediated killing by phagocytes [76], it is activated by physical
sequentially with those recovered early in treatment at the top and those recovered late at the bottom; the FL-sensitive strain SC5314 is included as a
control. Data was analyzed after growth for 48 hours at 30uC as in Figure 1A. (B) Inhibition of Hsp90 or Pkc1 abrogates FL resistance of both S.
cerevisiae and C. albicans erg3 mutants. Inhibition of Hsp90 or Pkc1 has no effect on the FL resistance of a S. cerevisiae strain (PDR1
R) that
overexpresses multiple drug efflux pumps due to an activating mutation in the transcription factor Pdr1. FL MIC assays were carried out in YPD
medium only (-) or in YPD with fixed concentrations of: geldanamycin (Sc:5mM; Ca: 0.625 mM), cercosporamide (Sc:5 0mg/ml; Ca:2 5mg/ml), or STS
(Sc: 0.625 mg/ml; Ca: 0.3125 mg/ml). Data was analyzed after growth for 48 hours at 30uC as in Figure 1A. The minimum drug concentration that
inhibits growth by 80% relative to the no-FL growth control (MIC80) is indicated for each strain.
doi:10.1371/journal.ppat.1001069.g008
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where the sole allele of HSP90 is under the control of a tetracycline repressible promoter (tetO), transcription of HSP90 can be repressed by
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biofilm development [77]. The mechanism by which Pkc1
influences virulence is distinct from calcineurin, which is required
for C. albicans virulence and survival in the bloodstream [67,68,69].
While the calcineurin mutant is unable to survive in serum, the
pkc1D/pkc1D mutant only exhibits an intermediate reduction in
viability (Figure 10B), suggesting that Pkc1 regulates virulence via
alternate targets. Notably, Pkc1 controls the expression of
numerous virulence determinants in the fungal pathogen Crypto-
coccus neoformans [78], suggesting that Pkc1 governs virulence in
phylogenetically diverse fungal species.
Our results suggest that targeting Pkc1 may provide a powerful
strategy for the treatment of fungal infectious disease. In vitro,
compromising PKC signaling renders laboratory strains and
clinical isolates hypersensitive to drugs targeting ergosterol
biosynthesis (Figures 1, 2, 3, and 8). These findings coupled with
those established by others linking PKC signaling to tolerance of
drugs targeting the cell wall [34,35,36,37], suggest that compro-
mising Pkc1 could have therapeutic benefits by enhancing the
efficacy of the two most widely deployed classes of antifungals, the
azoles and echinocandins. In a murine model of disseminated
candidiasis, deletion of PKC1 attenuates C. albicans virulence
(Figure 10A), suggesting therapeutic benefit of simply compromis-
ing fungal Pkc1 in addition to the benefits of combinatorial
therapeutic strategies. Notably, in mammalian cells disruption of
PKC signaling impairs tumor progression and drug resistance such
that PKC inhibitors have entered clinical trials for the treatment of
several human cancers as single or combination therapy agents
[79,80]. The complexity of functions and interactions of
mammalian PKC isoforms poses a challenge for the development
of anti-cancer therapeutics and current efforts focus on enhancing
specificity of action to target specific isoforms. While C. albicans
and other fungal pathogens only have one PKC isoform, the
therapeutic challenge will lie in achieving fungal selectivity. The
successful development of Hsp90 and calcineurin as therapeutic
targets for fungal disease faces similar challenges due to
complications of inhibiting the function of these key cellular
regulators in the host [66,81,82]. As a complement to identifying
fungal selective pharmacological agents, elucidating the architec-
ture of cellular circuitry governing stress responses, drug
resistance, and virulence is poised to reveal promising therapeutic




All procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) at Duke University according to the
guidelines of the Animal Welfare Act, The Institute of Laboratory
Animal Resources Guide for the Care and Use of Laboratory
Animals, and Public Health Service Policy.
Strains and culture conditions
Archives of C. albicans and S. cerevisiae strains were maintained at
280uC in 25% glycerol. Strains were grown in either yeast
peptone dextrose (YPD, 1% yeast extract, 2% bactopeptone, 2%
glucose) or in synthetic defined medium (SD, 0.67% yeast nitrogen
base, 2% glucose) and supplemented with amino acids or in RPMI
medium 1640 (Gibco SKU#318000-089, 3.5% MOPS, 2%
glucose, pH 7.0) supplemented with amino acids. 2% agar was
added for solid media. Strains were transformed following
standard protocols. Strains used in this study are listed in Table
S1. Strain construction is described in Text S1.
Plasmid construction
Recombinant DNA procedures were performed according to
standard protocols. Plasmids used in this study are listed in Table
S2. Plasmid construction is described in Text S1. Plasmids were
sequenced to verify the absence of any nonsense mutations.
Primers used in this study are listed in Table S3.
Isolation and characterization of cercosporamide
A seed culture of the fungus, Mycosphaerella (Cercosporidium)
henningsii (IMI 176827) grown on potato dextrose agar (PDA) for
two weeks was used for inoculation. Mycelia were scraped out and
mixed with 20 mL sterile water and filtered through a 100 mm
filter. Absorbance of the spore suspension was measured and
adjusted to 0.4. A 2 L Erlenmeyer flask containing 1 L of M-1-D
medium [83] was inoculated with 10 mL of the spore suspension
and incubated at 160 rpm and 28uC for four weeks. Mycelia were
then separated from the supernatant by filtration through
Whatman No. 1 filter paper and the filtrate was extracted with
EtOAc (66500 mL). The combined EtOAc extracts were washed
with H2O( 3 6500 mL), dried over anhydrous Na2SO4 and
evaporated under reduced pressure to yield a dark brown semi-
solid (51.2 mg). A portion (50.0 mg) of the EtOAc extract was
separated on preparative TLC (Merck, TLC silica gel 60 F254
precoated Aluminum sheets) using MeOH/Et2O (3:97) as eluant
affording crude cercosporamide (8.1 mg, Rf 0.4). This was further
purified by reversed-phase preparative TLC (Merck, TLC Silica
gel 60 RP-18 F254 precoated Aluminium sheets) using H2O/
CH3CN (3:7) as eluant to give pure cercosporamide (4.5 mg,
Rf 0.5).
Cercosporamide: red crystals; mp 187–188uC (lit. [46] 188–




NMR spectroscopic data were consistent with those reported in
the literature [46]. The structure of cercosporamide is shown in
Figure S9.
Minimum inhibitory concentration and checkerboard
assays
Antifungal tolerance and resistance were determined in flat
bottom, 96-well microtiter plates (Sarstedt) using a modified broth
microdilution protocol as described [25,27]. Dimethyl sulfoxide
(DMSO, Sigma Aldrich Co.) was the solvent for fenpropimorph
(FN, Sigma Aldrich Co) and terbinafine (TB, Sigma Aldrich Co.);
fluconazole (FL, Sequoia Research Products) and micafungin (MF,
generously provided by Julia R. Ko ¨hler) were dissolved in sterile
ddH2O. Geldanamycin (GdA, A.G. Scientific, Inc.) was used to
inhibit Hsp90 at the indicated concentrations. Cyclosporin A
(CsA, Calbiochem) was used to inhibit calcineurin at the indicated
tetracycline or the analog doxycycline (DOX). One allele of MKC1 was C-terminally 6xHis-FLAG tagged for monitoring total levels of Mkc1. The
MAPKKK Bck1 was deleted to block phosphorylation of Mkc1. Cells were grown with or without DOX (20 mg/ml) before being treated for 3 hours with
50 mg/ml terbinafine (TB) to elicit phosphorylation of Mkc1. Total protein was resolved by SDS-PAGE and blots were hybridized with a-Hsp90, a-His6
to monitor total Mkc1 levels, a-phospho p44/42 MAPK to monitor dually phosphorylated Mkc1 levels, and a-H3 as a loading control. (B) Simplified
schematic of how C. albicans Hsp90 governs responses to ergosterol biosynthesis inhibitors (EBIs) important for basal tolerance and resistance by
regulating both Pkc1-MAPK signaling and calcineurin signaling.
doi:10.1371/journal.ppat.1001069.g009
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Scientific, Inc.) were used to inhibit protein kinase C at the
indicated concentrations. DMSO was the solvent for GdA, CsA,
STS, and cercosporamide.
Minimum inhibitory concentration (MIC) tests were set up in a
total volume of 0.2 ml/well with 2-fold dilutions of FL, FN, TB
and cercosporamide. FL gradients were from 256 mg/ml down to
0 with the following concentration steps in mg/ml: 256, 128, 64,
Figure 10. Deletion of C. albicans PKC1 attenuates virulence in a murine model by targets distinct from calcineurin. (A) CD1 mice were
infected with an inoculum of the wild-type strain (SN95) of 1610
5 CFU or inoculum of the pkc1D/pkc1D mutant of 1610
5 CFU, 1610
6 CFU, or 1610
7
CFU. Despite the higher innoculum used, deletion of PKC1 resulted in a dramatic reduction of kidney fungal burden. Asterisks indicate P,0.001
(ANOVA, Bonferroni’s Multiple Comparison Test). (B) Deletion of PKC1, but not components of the MAPK cascade, results in a modest increase in
sensitivity to serum compared to the hypersensitivity of a mutant lacking the catalytic subunit of calcineurin, Cna1. Cells were spotted in fivefold
dilutions (from 1610
7 cells/ml for pkc1D/pkc1D; from 1610
6 cells/ml for other strains) onto solid YPD medium with 50% new calf serum (NCS), as
indicated. Plates were photographed after 72 hours growth at 35uC.
doi:10.1371/journal.ppat.1001069.g010
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down to 0 with the following concentration steps in mg/ml: 25,
12.5, 6.25, 3.125, 1.5625, 0.78125, 0.390625, 0.1953125,
0.09765625, 0.04882813, 0.02441406. TB gradients were from
250 mg/ml with the following concentration steps in mg/ml: 250,
125, 62.5, 31.25, 15.625, 7.8125, 3.90625, 1.953125, 0.9765625,
0.48828125, 0.24414063. Cercosporamide gradients were from
100 mg/ml with the following concentration steps in mg/ml: 100,
50, 25, 12.5, 6.25, 3.125, 1.5625, 0.78125, 0.390625, 0.1953125,
0.09765625. Cell densities of overnight cultures were determined
and dilutions were prepared such that ,10
3 cells were inoculated
into each well. Plates were incubated in the dark at 30uCo r3 5 uC
for the period of time indicated in the figure legend, at which point
plates were sealed with tape and re-suspended by agitation.
Absorbance was determined at 600 nm using a spectrophotometer
(Molecular Devices) and corrected for background from the
corresponding medium. Each strain was tested in duplicate on at
least 3 occasions. MIC data was quantitatively displayed with
color using the program Java TreeView 1.1.1 (http://jtreeview.
sourceforge.net).
Checkerboard assays were set up in a total volume of 0.2 ml/
well with 2-fold dilutions of cyclosporin A across the x-axis of the
plate and 2-fold dilutions of STS across the y-axis of the plate. STS
gradients were from 0.5 mg/ml to 0 in the following concentrations
steps in mg/ml: 0.5, 0.25, 0.125, 0.0625, 0.03125, 0.015625,
0.0078125. CsA gradients were from 48 mg/ml down to 0 in the
following concentration steps in mM: 48, 24, 12, 6, 3, 1.5, 0.75,
0.375, 0.1875, 0.09375, 0.046875. Plates were inoculated and
growth was measured as with MIC tests. To test for synergy, the
fractional inhibitory concentration (FIC) was calculated as follows:
[(MIC80 of drug A in combination)/(MIC80 of drug A alone)] +
[(MIC80 of drug B in combination)/(MIC80 of drug B alone)].
Values of #0.5 indicate synergy, those of .0.5 but ,2 indicate no
interaction and those $2 indicate antagonism.
Spotting assays
Strains were grown overnight to saturation in indicated media
and cell concentrations were determined based on cell counts
using a hemacytometer (Hausser Scientific). Five-fold serial
dilutions of cell suspensions starting at indicated concentrations
(10
5 or 10
7cells/ml) were performed in sterile ddH2O or sterile
phosphate buffered saline. Cell suspensions were spotted onto
indicated media using a spotter (Frogger, V&P Scientific, Inc).
Plates were photographed after 3 days in the dark at indicated
temperature.
Cidality assay
For S. cerevisiae, MIC assays with two-fold dilutions of FL, FN, or
TB were performed in SD as described above. For FL the
gradients were from 256 mg/ml down to 0 with the following
concentration steps in mg/ml: 256, 128, 64, 32, 16. FN gradients
were from 100 mg/ml down to 0 with the following concentration
steps in mg/ml: 100, 50, 25, 12.5, 6.25. TB gradients were from
250 mg/ml with the following concentration steps in mg/ml: 250,
125, 62.5, 31.25, 15.62. Plates were incubated for two days at
35uC. Cells from the MIC assay were spotted onto solid YPD
medium and incubated at 30uC for two days before they were
photographed.
For C. albicans, MIC assays with FL, FN, or TB were performed
in YPD as described above with the following modification; four-
fold dilutions of each drug were tested. For FL the gradients were
from 256 mg/ml down to 0 with the following concentration steps
in mg/ml: 256, 64, 16, 4, 1. FN gradients were from 25 mg/ml
down to 0 with the following concentration steps in mg/ml: 25,
6.25, 1.5625, 0.390625, 0.09765625. TB gradients were from
250 mg/ml with the following concentration steps in mg/ml: 250,
62.5, 15.625, 3.90625, 0.9765625. Plates were incubated for two
days at 35uC. Cells from the MIC assay were spotted onto solid
YPD medium and incubated at 30uC for two days before they
were photographed.
b-galactosidase assays
S. cerevisiae cultures were grown overnight at 25uCi nS D
medium supplemented for auxotrophies. Cells were diluted to
OD600 of 0.05 and were either left untreated or were treated with
FL (16 mg/ml), FN (1 mg/ml), or TB (25 mg/ml) for 24 hours at
25uC. When STS was used as an inhibitor in the assay, cultures
were grown overnight in SD at 25uC and diluted to OD600 of 0.05
in SD with or without STS (2.5 mg/ml) for 24 hours at 25uC. Cells
were then diluted to OD600 of 0.05 in SD with or without STS and
with or without FL (32 mg/ml) for an additional 24 hours at 25uC.
Cells were harvested, washed, protein was extracted, and protein
concentrations were determined by Bradford analysis as described
[27]. Protein samples were diluted to the same concentration and
b-galactosidase activity was measured using the substrate ONPG
(O-nitrophenyl-b-D-galactopyranosidase, Sigma Aldrich Co.) as
described [27]. b-galactosidase activity is given in units of
nanomoles ONPG converted per minute per milligram of protein.
Statistical significance was evaluated using GraphPad Prism 4.0.
Immune blot analysis
For the Mkc1 activation assay, yeast cultures were grown
overnight in YPD at 30uC. In the morning, cells were diluted to
OD600 of 0.2 in 50 mL YPD and were grown to mid-log
(,3 hours) at 30uC and then cultures were split into 5610 mL
cultures and were either left untreated or were treated with FL
(8 mg/mL), FN (1 mg/mL), MF (30 ng/mL), or TB (25 mg/ml) for
2 hours at 30uC. Cells were harvested by centrifugation at 13086g
for 10 minutes at 4uC and were washed with sterile cold phosphate
buffered saline (PBS). Cell pellets were resuspended in lysis buffer
containing 50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1%Triton 6100, 50 mM NaF, 10 mM Na3VO4,1m M
PMSF, and protease inhibitor cocktail (complete, EDTA-free
tablet, Roche Diagnostics).
For the Mkc1 destabilization assay, cultures were grown
overnight in YPD at 30uC. In the morning, cells were diluted to
OD600 of 0.2 in 10 mL YPD with or without doxycycline (20 mg/
mL; BD Biosciences) and left at 30uC for 24 hours. Cells were
diluted once again to OD600 of 0.2 in the same treatment
conditions as overnight and were grown at 30uC until mid-log
phase (,4 hours). Doxycycline reduces the growth rate of strains
with the repressible promoter driving expression of the only
HSP90 allele but does not affect stationary phase cell density [65].
Cells were then treated with 50 mg/mL TB for 3 hours at 30uCt o
elicit phosphorylation of Mkc1. Cells were harvested after TB
treatment at 13086ga t4 uC and washed with ice-cold ddH2O.
Cell pellets were flash frozen in liquid N2, resuspended in lysis
buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM EDTA,
1% Triton 6100, 100 mM NaF, 20 mM Na3VO4, 1 mM PMSF
and protease inhibitor cocktail complete, EDTA-free tablet,
Roche Diagnostics).
Cells suspended in lysis buffer were mechanically disrupted by
adding acid-washed glass beads and bead beating for 1 minute for
six cycles with 1 minute on ice between each cycle. Protein
concentrations were determined by Bradford analysis. Protein
samples were mixed with one-sixth volume of 66 sample buffer
containing 0.35 M Tris-HCl, 10% (w/w) SDS, 36% glycerol, 5%
b-mercaptoethanol, and 0.012% bromophenol blue for SDS-
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10% SDS-PAGE. Protein was electrotransferred to PVDF
membrane (Bio-Rad Laboratories, Inc.) and blocked with 5%
skimmed milk in PBS with 0.1% tween or 5% bovine serum
albumin in phosphate buffered saline with 0.1% tween. Blots were
hybridized with antibodies against CaHsp90 (1:10000 dilution,
generously provided by Brian Larsen, [84]), histone H3 (1:3000
dilution; Abcam ab1791), His6 (1:10, P5A11, generously provided
by Elizabeth Wayner) and phospho-p44/42 MAPK (Thr202/
Tyr204) (1:2000, Cell Signaling).
Quantitative reverse transcription-PCR (qRT-PCR)
To monitor gene expression changes in response to FL
treatment in S. cerevisiae, cells were grown overnight in SD
supplemented for auxotrophies at 30uC. Cells were diluted to
OD600 of 0.1 in SD and grown for 2 hours in duplicate at 25uC.
After 2 hours of growth 16 mg/mL FL was added to one of the two
duplicate cultures and left to grow for an additional 4 hours at
25uC. Cell pellets were frozen at 280uC immediately.
To monitor gene expression changes in response to FL
treatment in C. albicans, cells were grown overnight in YPD at
30uC. Cells were diluted to OD600 of 0.1 in YPD and grown for
2 hours in duplicate at 35uC. After 2 hours of growth 16 mg/mL
FL was added to one of the two duplicate cultures and left to grow
for an additional 4 hours at 35uC. Cell pellets were frozen at
280uC immediately.
To monitor MKC1 transcript levels in response to decreased
levels of Hsp90, cultures were grown overnight in YPD at 30uC. In
the morning, cells were diluted to OD600 of 0.2 in 10 mL YPD
with or without 20 mg/mL doxycycline (BD Biosciences) and left
at 30uC for 24 hours. The next morning, cells were diluted once
again to OD600 of 0.2 in the same treatment conditions and were
grown at 30uC until mid-log phase (,4 hours). Cell pellets were
collected and immediately frozen at 280uC.
RNA was isolated using the QIAGEN RNeasy kit and RNAase-
free DNase (QIAGEN), and cDNA synthesis was performed using
the AffinityScript cDNA synthesis kit (Stratagene). PCR was
performed using SYBR Green JumpStart Taq ReadyMix (Sigma-
Aldrich Co.) with the following cycling conditions: 94uC for
2 minutes, 94uC for 15 seconds, 60uC for 1 minute, 72uC for
1 minute, for 30 or 40 cycles. All reactions were performed in
triplicate, using primers for the following genes: CaGPD1
(oLC752/753), CaHSP90 (oLC754/755), ScACT1 (oLC1015/
1016), ScCNA1 (oLC1286/1287), ScCNA2 (oLC1288/1289),
ScCNB1(oLC1290/1291), CaCNB1 (oLC1292/1293), CaCNA1
(oLC1294/1295), ScCRZ1 (oLC1328/1329), CaCRZ1(oLC1330/
1331), CaMKC1(oLC1332/1333), CaPLC3(oLC1432/1433), and
CaUTR2(oLC1434/1435). Data were analyzed using iQ5 Optical
System Software Version 2.0 (Bio-Rad Laboratories, Inc.).
Statistical significance was evaluated using GraphPad Prism 4.0.
Murine model of C. albicans infection
Inoculum was prepared as described [20,27,65]. Cultures were
started from frozen stocks onto Sabouraud dextrose agar plates and
incubated at 35uC for 48 hours. Colonies were suspended in sterile
pH 7.4 PBS, centrifuged at 3246g for 5 minutes, washed with
sterile PBS one time and diluted to the desired concentration as
verified by counting on a Neubauer hematocytometer as well as by
serial dilution and culture. Male CD1 mice (Charles River
Laboratories, Wilmington, MA) age 8 weeks (weight 30–34 g) were
infected via the tail vein with 100 mLo fa1 610
6 CFU/mL
suspension of the wild type strain (CaLC239, 1610
5 CFU per
mouse, n=9 mice), an inoculum previously determined to produce
morbidity but not mortality when using C. albicans strain SC5314 at
4 days following tail vein injection (Zaas et al. unpublished data). We
observed discordance between cell counts and CFU measurements
for the pk1cD/pkc1D mutant, such that CFU values were ,50%
lower than expected;thus, inoculafor the pk1cD/pkc1D mutant were
prepared at higher concentrations based on cell counts and the
effective concentrations in CFUs were confirmed by dilution
plating. For infection with the pk1cD/pkc1D mutant, we used an
inoculum equivalent to that for the wild type (1610
5 CFU, n=8
mice) as well a 10-fold and 100-fold increase in inoculum (1610
6,
n=11miceand1 610
7 CFU, n=8 mice). Mice were observed three
times daily for signs of illness and weighed daily. At day 4 following
injection, mice were sacrificed using CO2 asphyxiation and the left
kidney was removed aseptically, placed in sterile PBS, homogenized
using a FastPrep 120 (QBiogene) using 0.5 mm zirconium beads
(Biospec, Inc.) for 1 minute and serial dilutions plated for
determination of kidney fungal burden. The CFU values in kidneys
were expressed as CFU/g of tissue and log-transformed. Statistical
significance was evaluated using GraphPad Prism 4.0.
Accession numbers for genes and proteins mentioned in
text (NCBI Entrez gene ID number)
S. cerevisiae: PKC1 (852169); HSC82 (855224); HSP82 (855836);
CNA1 (851153); CNA2 (854946); CNB1 (853644); ERG11 (856398);
ERG3 (850745); RHO1 (856294); BCK1 (853350); MKK1 (854406);
MKK2 (855963); SLT2 (856425); SWI4 (856847); SWI6 (850879);
ERG2 (855242); ERG24 (855441); ERG1 (853086); RLM1
(856016); CCH1 (853131); MID1 (855425); CRZ1 (855704);
PDR5 (854324); PDR1 (852871); PDR3 (852278); ACT1 (850504).
C. albicans PKC1 (3635298); HSP90 (3637507); CNA1 (3639406);
CNB1 (3636463); MKC1 (3639710); ERG11 (3641571); ERG3
(3644776); RHO1 (3642564); BCK1 (3641434); MKK2 (3645580);
MDR1 (3639260); ERG2 (3639416); ERG24 (3648198); ERG1
(3646509); CEK1 (3642789); CEK2 (3642459); RLM1 (3635703);
SWI4 (3645507); SWI6 (3634957); CCH1 (3639950); MID1
(3647441); CRZ1 (3641722); PLC3 (3635941); UTR2 (3636747);
CDR1 (3635385); GPD1 (3643986).
Supporting Information
Figure S1 Pkc1-MAPK signaling enables tolerance to ergosterol
biosynthesis inhibitors in S. cerevisiae.( A) At the permissive
temperature, the pkc1-ts mutant and the wild-type (WT) strain
(BY4741) have comparable tolerance to all three ergosterol
biosynthesis inhibitors tested. Assays were performed in synthetic
defined (SD) medium at 35uC. Data was analyzed after 48 hours
as in Figure 1A. (B) Genetic compromise of Pkc1 function reduces
ergosterol biosynthesis inhibitor tolerance on solid SD medium.
Drug tolerance of a WT strain (BY4741) and a derivative (pkc1-ts)
with a temperature sensitive PKC1 allele spotted in fivefold
dilutions (from 1610
7 cells/ml) onto plates with no antifungal (-) or
with a fixed concentration of fluconazole (FL, 16 mg/mL),
terbinafine (TB, 30 mg/mL), or fenpropimorph (FN, 0.5 mg/
mL), as indicated. Plates were incubated at 30uCo r3 5 uC and
were photographed after 72 hours at the indicated temperatures.
(C) Deletion of components of the MAPK cascade, BCK1 and
SLT2, reduces ergosterol biosynthesis inhibitor tolerance on solid
SD medium. Assays were performed as indicated in (A) and plates
were incubated 35uC and photographed after 72 hours.
Found at: doi:10.1371/journal.ppat.1001069.s001 (2.41 MB TIF)
Figure S2 Restoring a wild-type PKC1 allele restores basal
tolerance to ergosterol biosynthesis inhibitors in C. albicans.( A)
Homozygous deletion of PKC1 reduces ergosterol biosynthesis
inhibitor tolerance on solid YPD medium and restoring a wild-
type PKC1 allele restores tolerance. Cells were spotted in fivefold
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7 cells/ml for pkc1D/pkc1D and from 1610
5
cells/ml for other strains) onto plates with no antifungal (-) or with
a fixed concentration of fluconazole (FL, 4mg/mL), terbinafine
(TB, 2.5mg/mL), or fenpropimorph (FN, 0.25mg/mL). Plates were
photographed after 72 hours growth at 35uC. (B) Homozygous
deletion of PKC1 confers hypersensitivity to all three ergosterol
biosynthesis inhibitors tested in MIC assays; restoring a wild-type
PKC1 allele under the control of the native promoter to the native
locus restores basal tolerance. Assays were performed in YPD
medium at 30uC with strains derived from the WT SN95. Data
was analyzed after 72 hours growth as in Figure 1A. (C)
Homozygous deletion of PKC1 renders the ergosterol biosynthesis
inhibitors fungicidal against C. albicans and restoring a wild-type
PKC1 allele restores the fungistatic activity. MIC assays with four-
fold dilutions of FL, FN, and TB were performed in YPD and
incubated for 48 hours at 35uC. Cells from the MIC assays were
spotted onto YPD medium and incubated at 30uC for 48 hours
before plates were photographed.
Found at: doi:10.1371/journal.ppat.1001069.s002 (1.85 MB TIF)
Figure S3 Involvement of the C. albicans MAPK cascade in
responses to ergosterol biosynthesis inhibitors at 30uC but not
35uC. (A) Exposure of C. albicans with ergosterol biosynthesis
inhibitors activates the MAPK cascade leading to the accumula-
tion of phosphorylated Mkc1. One allele of MKC1 was C-
terminally 6xHis–FLAG tagged in this strain. Cells were grown to
mid-log before being treated for 2 hours at 30uC as follows:
untreated (-); FN, 1 mg/mL; FL, 8 mg/mL; TB, 25 mg/mL; or MF,
30 ng/mL. Total protein resolved by SDS-PAGE was blotted with
a-His6 to monitor total Mkc1 levels and a-phospho p44/42
MAPK to monitor dually phosphorylated Mkc1 levels. (B)
Deletion of BCK1 and MKC1 does not increase sensitivity to
fluconazole (FL), fenpropimorph (FN), or terbinafine (TB) in MIC
assays performed in YPD medium at 35uC. Data was analyzed
after 72 hours as in Figure 1A.
Found at: doi:10.1371/journal.ppat.1001069.s003 (0.31 MB TIF)
Figure S4 Pkc1 enables tolerance to ergosterol biosynthesis
inhibitors in S. cerevisiae via the MAPK cascade at 30uC. Deletion
of components of the MAPK cascade in the BY4741 background
confers hypersensitivity to ergosterol biosynthesis inhibitors in
MIC assays conducted in SD at 30uC. Data was analyzed after
48 hours as in Figure 1A.
Found at: doi:10.1371/journal.ppat.1001069.s004 (0.18 MB TIF)
Figure S5 Genetic perturbation of PKC signaling in S. cerevisiae
does not compromise expression of calcineurin subunits or CRZ1.
Deletion of SLT2 does not reduce expression of calcineurin subunits
or CRZ1 in the presence or absence of ergosterol biosynthesis
inhibitors. Transcript levels of the genes encoding the catalytic
subunit (CNA1 and CNA2) and the regulatory subunit (CNB1)o f
calcineurin and CRZ1 were measured by quantitative RT-PCR after
growth in SD at 25uC for 6 hours without any antifungal (U) or for
twohoursuntreatedfollowedby4 hourswith16 mg/mLfluconazole
(FL), as indicated. Transcripts were normalized to ACT1.L e v e l sa r e
expressed relative to the untreated wild-type samples, which were set
to 1. Data are means 6 SD for triplicate samples.
Found at: doi:10.1371/journal.ppat.1001069.s005 (0.46 MB TIF)
Figure S6 Inhibition of Pkc1 signaling phenocopies inhibition of
Hsp90 reducing azole resistance of specific mutants. Azole
resistance of matched sets of C. albicans clinical isolates (CaCi)
taken from HIV-infected patients early (E) and late (L) during the
course of fluconazole (FL) treatment is tested in MIC assays.
Assays were conducted in YPD medium with no inhibitor (-), with
the Hsp90 inhibitor geldanamycin (5 mM), or with the Pkc1
inhibitor staurosporine (0.5 mg/ml). Mutations implicated in azole
resistance for each isolate are indicated. Data was analyzed after
growth for 48 hours at 30uC as in Figure 1A.
Found at: doi:10.1371/journal.ppat.1001069.s006 (0.26 MB TIF)
Figure S7 The C-terminal 6xHis-FLAG epitope tag does not
disrupt functionality of C. albicans Mkc1. When MKC1-6xHis-FLAG
is expressed as the sole copy MKC1, it is sufficient to confer WT
tolerance to the ergosterol biosynthesis inhibitors in MIC assays.
Assays were performed in YPD and growth was measured after
48 hours at 30uC. Data was analyzed and plotted as in Figure 1A.
Found at: doi:10.1371/journal.ppat.1001069.s007 (0.26 MB TIF)
Figure S8 Genetic depletion of Hsp90 does not affect MKC1
transcript levels. In strains where the sole allele of HSP90 is under
the control of a tetracycline repressible promoter (tetO), transcrip-
tion of HSP90 can be repressed by tetracycline or the analog
doxycycline. Cells were grown in YPD with or without
doxycycline (20 mg/ml) and MKC1 transcript levels were measured
by quantitative RT-PCR. Transcripts were normalized to GPD1.
Levels are expressed relative to the untreated wild-type samples,
which were set to 1. Data are means 6 SD for triplicate samples.
Found at: doi:10.1371/journal.ppat.1001069.s008 (0.40 MB TIF)
Figure S9 Structure of cercosporamide. The structure of
cercoposamide was made using ChemDraw Pro (CyberChem,
Inc.).
Found at: doi:10.1371/journal.ppat.1001069.s009 (0.05 MB TIF)
Table S1 Strains used in this study.
Found at: doi:10.1371/journal.ppat.1001069.s010 (0.17 MB
DOC)
Table S2 Plasmids used in this study
Found at: doi:10.1371/journal.ppat.1001069.s011 (0.03 MB
DOC)
Table S3 Primers used in this study.
Found at: doi:10.1371/journal.ppat.1001069.s012 (0.04 MB
DOC)
Text S1 Supporting Materials and Methods.
Found at: doi:10.1371/journal.ppat.1001069.s013 (0.06 MB
DOC)
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